What is Veracyte?
Founded in 2006 and headquartered in San Francisco, Veracyte is a leader in the field of molecular cytology. The company specializes in developing advanced molecular tests that significantly enhance the diagnostic accuracy of cytology samples. By providing clinicians with actionable insights, Veracyte facilitates the use of minimally invasive procedures as a superior alternative to traditional surgical biopsies. This focus on patient-centric, high-utility diagnostic solutions has positioned the firm as a critical player in the modern healthcare ecosystem, bridging the gap between complex genomic data and clinical decision-making.
How much funding has Veracyte raised?
Veracyte has raised a total of $640.9M across 10 funding rounds:
Series B
$28M
Series C
$28M
Stock Offering
$58M
Share Placement
$40M
Debt
$45M
Stock Offering
$31.9M
Stock Offering
$55.1M
Stock Offering
$137.9M
Stock Offering
$194M
Series B (2010): $28M led by KPCB Holdings, Versant Ventures, Domain Associates, and TPG Biotech
Series C (2013): $28M supported by KPCB Holdings, Versant Ventures, Domain Associates, GE Ventures, and TPG Biotech
Stock Issuance/Offering (2013): $58M featuring Undisclosed
Share Placement (2015): $40M backed by venBio, Deerfield, Broadfin Capital, Camber Capital, and Longwood Capital Partners
Debt (2016): $45M with participation from Visium Healthcare Partners
Stock Issuance/Offering (2016): $31.9M led by Undisclosed
Stock Issuance/Offering (2018): $55.1M supported by Undisclosed
Stock Issuance/Offering (2019): $137.9M featuring Undisclosed
Stock Issuance/Offering (2020): $194M backed by Undisclosed
Key Investors in Veracyte
KPCB Holdings
Kleiner Perkins is a Menlo Park-based venture capital firm that invests in early and growth-stage technology and life-science companies, providing operational support from seed through IPO.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies globally, leveraging extensive backgrounds in pharmaceuticals and scientific research.
Domain Associates
Domain Associates is an investment advisory firm established in 1985, specializing in biotech investments with a strong track record of supporting biopharmaceutical and diagnostic companies.
What's next for Veracyte?
With a solid foundation of $640.9M in historical capital, Veracyte is well-positioned to scale its diagnostic platform and expand its clinical footprint. The recent $194M injection provides the necessary liquidity to accelerate research and development, potentially broadening its test menu to address additional unmet medical needs. As the company continues to leverage its proprietary technology, the focus will likely shift toward global market penetration and the integration of its diagnostic tools into standard clinical workflows, further cementing its status as a cornerstone of precision medicine.
See full Veracyte company page
